$2.95
+0.30 (+11.32%)
Open$2.70
Previous Close$2.65
Day High$2.96
Day Low$2.65
52W High$12.23
52W Low$2.65
Volume—
Avg Volume270.8K
Market Cap72.00M
P/E Ratio—
EPS$-0.92
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,626.1% upside
Current
$2.95
$2.95
Target
$50.92
$50.92
$37.48
$50.92 avg
$70.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 77.20M | 68.03M | 17.09M |
| Net Income | -23,134,389 | -18,347,682 | -4,142,594 |
| Profit Margin | -30.0% | -28.5% | -24.3% |
| EBITDA | -15,947,079 | -13,350,127 | -7,262,848 |
| Free Cash Flow | — | — | -5,494,601 |
| Rev Growth | +13.5% | +13.5% | +9.1% |
| Debt/Equity | 1.49 | 1.49 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |